Adult Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia in Daily Practice: A Multicenter Experience

Basit Öğe Kaydı
dc.authorid0000-0001-8359-7794
dc.authorid0000-0002-2035-9462
dc.authorid0000-0001-6872-3780
dc.authorscopusid15756259700
dc.authorscopusid57203104682
dc.authorscopusid25639501700
dc.authorscopusid56985556700
dc.authorscopusid53983007800
dc.authorscopusid55212747300
dc.authorscopusid25226265900
dc.authorwosidbozdağ, sinem civriz/AAQ-4752-2020
dc.authorwosidBuyukasik, Yahya/AAJ-3228-2020
dc.authorwosidOzturk, Erman/A-1612-2019
dc.authorwosidTurgut, Burhan/A-2517-2016
dc.authorwosidDogu, Mehmet Hilmi/W-2255-2017
dc.authorwosidKaynar, Leylagul/F-6991-2013
dc.authorwosidAltuntas, Fevzi/E-8945-2015
dc.contributor.authorTekgündüz, Emre
dc.contributor.authorGöker, Hakan
dc.contributor.authorKaynar, Leylagül
dc.contributor.authorSarı, İsmail
dc.contributor.authorPala, Çiğdem
dc.contributor.authorDoğu, Mehmet Hilmi
dc.contributor.authorAltuntaş, Fevzi
dc.contributor.authorTurgut, Burhan
dc.date.accessioned2022-05-11T14:39:54Z
dc.date.available2022-05-11T14:39:54Z
dc.date.issued2016
dc.departmentFakülteler, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, İç Hastalıkları Ana Bilim Dalı
dc.description.abstractIn this retrospective, multicenter study, we evaluated the real-life outcomes of adult Philadelphia-positive acute lymphoblastic leukemia patients. The best results in terms of survival are achieved in patients who were treated with tyrosine kinase inhibitors during induction and received allogeneic hematopoietic cell transplantation as part of consolidation. Background: The prognosis of Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL) is generally poor. Currently, allogeneic hematopoietic cell transplantation (allo-HCT) is the only accepted therapy with curative potential. Patients and Methods: Herein, we report our multicenter, retrospective experience with 46 (23 female; 23 male) Ph+ ALL patients, who were treated off-study between 2005 and 2012. Results: The median age of the patients was 46 years (range, 19-73 years). During induction, 30 (65%), 13 (28%), and 3 (7%) patients received tyrosine kinase inhibitors (TKIs) concurrent with chemotherapy (TKIs/chemotherapy), chemotherapy only, and TKIs only, respectively. Following induction, rates of complete remission (CR) of the study population were 85% (n = 39). CR rate in patients receiving TKIs during induction (n = 33) was significantly higher compared with patients who received chemotherapy only (n = 13; P = .011). Taking TKIs during induction significantly reduced induction mortality (3.3% vs. 38%; P = .01). Allo-HCT was performed subsequently in 21 (46%) patients. More patients who received TKIs with or without chemotherapy (19/33; 58%) during induction were able to undergo to allo-HCT compared with patients who received chemotherapy only (2/13; 15%; P = .005). Median overall survival of patients who were treated with TKIs during induction and received allo-HCT (not reached; NR) was significantly prolonged compared with patients who received allo-HCT but without TKIs during induction (23.2 months) and to the rest of the cohort (21.2 months; P = .019). Conclusions: Current state-of-the art management of Ph+ ALL in real-life seems to be incorporation of TKIs to chemotherapy regimens and proceeding to allo-HCT, whenever possible. (C) 2016 Elsevier Inc. All rights reserved.
dc.description.sponsorshipNATIONAL CANCER INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [U01CA176063] Funding Source: NIH RePORTER
dc.identifier.doi10.1016/j.clml.2016.01.007
dc.identifier.endpage274
dc.identifier.issn2152-2650
dc.identifier.issn2152-2669
dc.identifier.issue5en_US
dc.identifier.pmid26927932
dc.identifier.scopus2-s2.0-84969172355
dc.identifier.scopusqualityQ2
dc.identifier.startpage269
dc.identifier.urihttps://doi.org/10.1016/j.clml.2016.01.007
dc.identifier.urihttps://hdl.handle.net/20.500.11776/8786
dc.identifier.volume16
dc.identifier.wosWOS:000375600700009
dc.identifier.wosqualityQ3
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.institutionauthorTurgut, Burhan
dc.language.isoen
dc.publisherCig Media Group, Lp
dc.relation.ispartofClinical Lymphoma Myeloma & Leukemia
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subjectAcute lymphoblastic leukemia
dc.subjectAllogeneic transplantation
dc.subjectBCR-ABL
dc.subjectPhiladelphia chromosome
dc.subjectStem cell transplantation
dc.subjectTerm-Follow-Up
dc.subjectBone-Marrow-Transplantation
dc.subjectCell Transplantation
dc.subjectHyper-Cvad
dc.subjectChemotherapy
dc.subjectImatinib
dc.subjectRemission
dc.subjectRegimen
dc.subjectConsolidation
dc.subjectInduction
dc.titleAdult Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia in Daily Practice: A Multicenter Experience
dc.typeArticle

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
8786.pdf
Boyut:
173.79 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text
İndir

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
Tıp Fakültesi Koleksiyonu